A study has found a link between obesity loss and weekly usage of semaglutide, a widely used treatment of diabetes. Acting like a human glucagon-like-peptide-1 in that increases insulin secretion, jabs could be a reality in the near future. The study, which has been published in the New England Journal of Medicine, says that in participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
A total of 1,961 participants were included in the 2021 study with a body mass index of more than 30, without having diabetes. They were assigned to 68 weeks of treatment with once-weekly semaglutide or placebo alongside lifestyle intervention. It found that more participants in the semaglutide group than in the placebo group achieved weight reductions of 5% or more. In the semaglutide group, the weight dropped by more than 15kg and in the placebo group it was 2.6kg.
However, the side effects of the trial resulted in nausea and in some instances, diarrhoea, which were typically mild-to-moderate in severity and subsided with time. The study still confirmed that lifestyle interventions and weekly semaglutide are helpful to reduce obesity. As per data from the World Health Organisation (WHO), worldwide obesity has nearly tripled since 1975, with many studies also associating higher risk of COVID with obesity.
WHO defines overweight and obesity as abnormal or excessive fat accumulation that may impair health. A person whose BMI is more than or equal to 25 is overweight and a person whose BMI is greater than 30 is considered obese.
#MaltaDaily